Characterizing Monocytes in Blood Disorders
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes-PHEMOP
NA · University Hospital, Angers · NCT06361641
This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers (other gov) |
| Locations | 3 sites (Angers, Maine et Loire and 2 other locations) |
| Trial ID | NCT06361641 on ClinicalTrials.gov |
What this trial studies
This study focuses on the functional and phenotypic characterization of monocytes in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. It aims to understand the role of monocytes and macrophages in the pathogenesis of these disorders, which are characterized by excessive production of myeloid cells due to specific genetic mutations. By analyzing monocyte signatures at diagnosis, the study seeks to uncover insights into the immune response and inflammation associated with MPNs. The findings could lead to a better understanding of the disease mechanisms and potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with polycythemia vera, essential thrombocythemia, or primary myelofibrosis who have not yet received specific treatment for their condition.
Not a fit: Patients with other hematological disorders or active cancers, as well as minors, are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new insights into the immune mechanisms underlying myeloproliferative neoplasms, potentially leading to improved treatment strategies.
How similar studies have performed: While the role of monocytes in MPNs has been underexplored, similar studies in other hematological conditions have shown promising results, indicating potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis) * Patient who has not received treatment specific to hemopathy at the time of sampling * Obtaining the signature of consent to participate in the study * Patient having consented to be included in the "Malignant Hemopathy" collection of Angers University Hospital and in FIMBANK database Exclusion Criteria: * Person not affiliated to a social security scheme or beneficiary of such a scheme * Patient with another hemopathy or another active cancer at the time of diagnosis * Minor patient at diagnosis (\< 18 years old) * Patient not capable or without agreement from the guardian or legal representative
Where this trial is running
Angers, Maine et Loire and 2 other locations
- GOUBAND Agathe — Angers, Maine et Loire, France (RECRUITING)
- BESCOND Charles — Cholet, Maine et Loire, France (NOT_YET_RECRUITING)
- TRUCHAN-GRACZYK Malgorzata — Saumur, Maine et Loire, France (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Agathe GOUBAND, PharmD — University Hospital
- Study coordinator: Agathe GOUBAND, PharmD
- Email: Agathe.Gouband@chu-angers.fr
- Phone: 02 41 35 55 96
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis